ATC класификация

Abrysvo (--) - Powder and solvent for solution for injection --¹ After reconstitution, one dose (0.5 mL) contains: RSV subgroup A stabilised prefusion F antigen*,** 60 micrograms RSV subgroup B stabilised prefusion F antigen*,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology

Adjupanrix (--) - Emulsion and suspension for emulsion for injection --¹ After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen* equivalent to: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14) 3.75 μg** * propagated in eggs ** haemagglutinin AS03 adjuvant composed of squalene (10.69 mg), DL-alfa-tocopherol (11.86 mg) and polysorbate 80 (4.86 mg)

Aflunov (--) - Suspension for injection --¹ Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/turkey/Turkey/1/2005 (H5N1) - like strain (NIBRG-23) (clade 2.2.1) 7.5 micrograms** per 0.5 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** expressed in microgram haemagglutinin Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams

Ambirix (--) - Suspension for injection --¹ 1 dose (1 ml) contains: Hepatitis A virus (inactivated)¹,² 720 ELISA Units Hepatitis B surface antigen³,⁴ 20 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ⁴Adsorbed on aluminium phosphate 0.4 milligrams Al³+

Anti-CHF Vaccine suspension for injection.

Avaxim 160 U adult 0,5 ml suspension for injection

Avaxim 80 U Pediatric 0,5 ml suspension for injection

BIMERVAX Bimervax (--) - Emulsion for injection --¹ One dose (0.5 mL) contains: 40 micrograms of selvacovatein adjuvanted with SQBA (EU/1/22/1709/001-004). Selvacovatein is a SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351 and B.1.1.7 strains) produced by recombinant DNA technology using a plasmid expression vector in a CHO cell line. SQBA adjuvant containing per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections.

Celldemic (--) - Suspension for injection --¹ One dose (0.5 ml) contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms** * propagated in Madin Darby Canine Kidney (MDCK) cells ** expressed in micrograms haemagglutinin. Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams

Cervarix (--) - Suspension for injection --¹ 1 dose (0.5 ml) contains: Human Papillomavirus1 type 16 L1 protein²,³,⁴ 20 micrograms Human Papillomavirus1 type 18 L1 protein²,³,⁴ 20 micrograms 1Human Papillomavirus = HPV ²adjuvanted by AS04 containing: 3-O-desacyl-4’- monophosphoryl lipid A (MPL)³ 50 micrograms ³ adsorbed on aluminium hydroxide, hydrated (Al(OH)₃) 0.5 milligrams Al³+ in total ⁴L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from Trichoplusia ni.

COMIRNATY 10 µg

COMIRNATY 30 µg

COMIRNATY 3 µg

COMIRNATY Omicron JN.1 10 µg - Omicron JN.1 (--) - Concentrate for dispersion for injection -¹⁷ COMIRNATY JN.1 10 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/034): After dilution, 1 dose (0.2 mL) contains 10 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

COMIRNATY Omicron JN.1 10 µg - Omicron JN.1 (--) - Dispersion for injection -¹⁶ COMIRNATY JN.1 10 micrograms/dose dispersion for injection (EU/1/20/1528/032-033) 1 dose (0.3 mL) contains 10 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

COMIRNATY Omicron JN.1 30 µg - Omicron JN.1 (--) - Dispersion for injection -¹⁵ COMIRNATY JN.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/028-031): 1 dose (0.3 mL) contains 30 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

COMIRNATY Omicron JN.1 3 µg - Omicron JN.1 (--) - Concentrate for dispersion for injection -¹⁸ COMIRNATY JN.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/035): After dilution, 1 dose (0.3 mL) contains 3 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

COMIRNATY Omicron JN.1 3 µg - Omicron JN.1 (--) - Concentrate for dispersion for injection -¹⁹ COMIRNATY JN.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/036): After dilution, 1 dose (0.2 mL) contains 3 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

COMIRNATY Omicron KP.2 10 µg - Omicron KP.2 (--) - Dispersion for injection -²¹ COMIRNATY KP.2 10 micrograms/dose dispersion for injection (EU/1/20/1528/0x-0y II-221 mock): 1 dose (0.3 mL) contains 10 micrograms mRNA encoding KP.2, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). The mRNA encoding KP.2 is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

COMIRNATY Omicron KP.2 30 µg - Omicron KP.2 (--) - Dispersion for injection -²⁰ COMIRNATY KP.2 30 micrograms/dose dispersion for injection (EU/1/20/1528/0xx-0xz ii-221 MOCK): 1 dose (0.3 mL) contains 30 micrograms mRNA encoding KP.2, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). The mRNA encoding KP.2 is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).